Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma

This is a prospective, open, multi-cohort phase II study The study included a screening period (participants signed informed consent no more than 28 days before the first treatment in the study), a treatment period (treatment termination was defined as termination of treatment for any reason, such as imaging confirmation of disease progression, failure to tolerate adverse effects after dose adjustment, or early withdrawal for any reason), and a follow-up period (including end-of-treatment visits, safety visits, and survival follow-up). Screening period: Participants are required to undergo a

Trial Details

NCT ID
NCT07909265
Phase
PHASE2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cadonilimab,Lenvatinib
Locations (sample)
  • Beijing, Panjiayuan Nanli, China|39.9075,116.39723

Key Eligibility Criteria

  • Sign written informed consent before enrollment;
  • Age ≥18 years old;
  • Histological and/or cytological diagnosis of unresectable advanced renal cell carcinoma;
  • Cohort 1: renal clear cell carcinoma, mainly renal clear cell carcinoma, was included. Patients progressed after previous treatment with immune che…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →